论文部分内容阅读
我国前列腺癌发病率呈逐年上升趋势,且大多数在发现时已处于中晚期,去势治疗(ADT)是目前治疗进展期前列腺癌的标准治疗方法,但在经历18~24个月的中位有效期之后,几乎所有患者都会激素抵抗大多数患者发展为去势抵抗性前列腺癌(CRPC),并且多数患者伴有骨转移以及远处脏器转移。虽然多西他赛一直作为一线治疗方案,但对于转移性去势抵抗性前列腺癌(mCRPC)的治疗仍然是一大难点。近几年一些新药物的出现,一些大型临床研究的支持,使得对mCRPC的治疗有了很大的突破,但合适的治疗策略、治疗顺序仍有很大的争论。在此篇综述中将对mCRPC的治疗进展做一个探讨,并提出合理的治疗策略。
The incidence of prostate cancer in our country is increasing year by year, and most of them are in the late stage of the discovery. Castration Therapy (ADT) is the standard treatment for advanced prostate cancer. However, after 18-24 months After the expiration date, almost all patients develop hormonal resistance in most patients with castrate resistant prostate cancer (CRPC), and most have bone metastases and distant organ metastases. Although docetaxel has been used as a first-line treatment, the treatment of metastatic castration-resistant prostate cancer (mCRPC) remains a major challenge. The emergence of some new drugs in recent years, the support of some large-scale clinical studies, made a great breakthrough in the treatment of mCRPC, but the appropriate treatment strategies, treatment sequence is still a lot of controversy. In this review, we will discuss the progress of mCRPC and propose a reasonable treatment strategy.